Literature DB >> 2751232

Responses of ewes to B. melitensis Rev1 vaccine administered by subcutaneous or conjunctival routes at different stages of pregnancy.

M P Jiménez de Bagués1, C M Marin, M Barberán, J M Blasco.   

Abstract

An experiment to determine the innocuousness and the humoral immune response of B. melitensis Rev1 vaccine was carried out in pregnant ewes. Thirty-three ewes were vaccinated on day 55 of pregnancy: 9 ewes received 2 X 10(9) Rev1 of French origin by the subcutaneous route, 9 ewes were conjunctivally vaccinated with 5 X 10(8) of the same strain, 7 ewes were subcutaneously vaccinated with 10(9) Rev1 of Spanish origin and 8 ewes received 1.8 X 10(9) Spanish strain Rev1 by conjunctival route. Another group (8 animals) were subcutaneously vaccinated with a reduced dose (10(6) of the French strain between days 90 and 120 of pregnancy. Finally, 20 ewes were vaccinated on day 120 of pregnancy with the French strain of which 11 received 10(9) Rev1 by the subcutaneous route and 9 were conjunctivally vaccinated with the same dose. Rev1 strain was isolated from the vaginal discharge of a significantly higher number of ewes vaccinated subcutaneously than in conjunctivally vaccinated ewes (24/35 versus 9/26 respectively; P less than 0.001). No difference between the two vaccine strains was recorded in the number of ewes excreting Rev1. Ewes subcutaneously vaccinated on day 55 of pregnancy aborted more frequently than conjunctivally vaccinated ewes (11/16 versus 2/17, respectively), hence a significantly reduced (P less than 0.001) length of pregnancy. Although 10 of the 11 animals subcutaneously vaccinated on day 120 of pregnancy excreted Rev1 strain, only one aborted. There was no significant effect of the time of vaccination on both abortions and length of pregnancy in ewes conjunctivally vaccinated with the French strain.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2751232

Source DB:  PubMed          Journal:  Ann Rech Vet        ISSN: 0003-4193


  9 in total

1.  Protection against brucellosis in goats, five years after vaccination with reduced-dose Brucella melitensis Rev 1 vaccine.

Authors:  E Díaz-Aparicio; L Hernández; F Suárez-Güemes
Journal:  Trop Anim Health Prod       Date:  2004-02       Impact factor: 1.559

2.  Protective properties of rifampin-resistant rough mutants of Brucella melitensis.

Authors:  R Adone; F Ciuchini; C Marianelli; M Tarantino; C Pistoia; G Marcon; P Petrucci; M Francia; G Riccardi; P Pasquali
Journal:  Infect Immun       Date:  2005-07       Impact factor: 3.441

3.  Vaccination with Brucella abortus rough mutant RB51 protects BALB/c mice against virulent strains of Brucella abortus, Brucella melitensis, and Brucella ovis.

Authors:  M P Jiménez de Bagüés; P H Elzer; S M Jones; J M Blasco; F M Enright; G G Schurig; A J Winter
Journal:  Infect Immun       Date:  1994-11       Impact factor: 3.441

4.  Progress in Brucella vaccine development.

Authors:  Xinghong Yang; Jerod A Skyberg; Ling Cao; Beata Clapp; Theresa Thornburg; David W Pascual
Journal:  Front Biol (Beijing)       Date:  2013-02-01

Review 5.  Molecular host-pathogen interaction in brucellosis: current understanding and future approaches to vaccine development for mice and humans.

Authors:  Jinkyung Ko; Gary A Splitter
Journal:  Clin Microbiol Rev       Date:  2003-01       Impact factor: 26.132

6.  Evaluation of the safety profile of the vaccine candidate Brucella melitensis 16MΔvjbR strain in goats.

Authors:  M Raquel Castaño-Zubieta; Carlos A Rossetti; Daniel G García-González; Estefanía Maurizio; Martha E Hensel; Allison C Rice-Ficht; Thomas A Ficht; Ángela M Arenas-Gamboa
Journal:  Vaccine       Date:  2020-12-13       Impact factor: 3.641

7.  Brucella melitensis Wzm/Wzt System: Changes in the Bacterial Envelope Lead to Improved Rev1Δwzm Vaccine Properties.

Authors:  Sara Mena-Bueno; Irati Poveda-Urkixo; Oihane Irazoki; Leyre Palacios; Felipe Cava; Ana Zabalza-Baranguá; María Jesús Grilló
Journal:  Front Microbiol       Date:  2022-07-04       Impact factor: 6.064

8.  Evaluation of shedding, tissue burdens, and humoral immune response in goats after experimental challenge with the virulent Brucella melitensis strain 16M and the reduced virulence vaccine strain Rev. 1.

Authors:  Jennifer L Higgins; Mercedes Gonzalez-Juarrero; Richard A Bowen
Journal:  PLoS One       Date:  2017-10-13       Impact factor: 3.240

9.  Vaccine safety studies of Brucella abortus S19 and S19ΔvjbR in pregnant swine.

Authors:  Slim Zriba; Daniel G Garcia-Gonzalez; Omar H Khalaf; Lance Wheeler; Sankar P Chaki; Allison Rice-Ficht; Thomas A Ficht; Angela M Arenas-Gamboa
Journal:  Vaccine X       Date:  2019-08-22
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.